Terms of Use

Index

PLEASE READ THESE TERMS OF USE CAREFULLY. These Terms of Use describe rules for visitors to this United Therapeutics Corporation website. This website is owned and operated by United Therapeutics Corporation. United Therapeutics Corporation is the name we use to refer to our whole business, including United Therapeutics Corporation, and any of the companies that it owns or controls, such as its subsidiaries and affiliates. When we use the words “we” or “our,” we mean United Therapeutics Corporation. United Therapeutics Corporation also operates other websites. These Terms of Use do not apply to our other websites. You should review the terms of use posted on these United Therapeutics Corporation websites when you visit them.

Please read this page carefully. By using this website, you agree to be bound by all of the Terms and Conditions set forth below. If you do not accept these Terms and Conditions, please do not use this website.

These Terms of Use were last updated in December, 2015. We may change these Terms of Use at any time. Please review the Terms of Use each time you visit the website. By using this website, it means you accept the most recent version of the Terms of Use.

CALL 911 FOR AN EMERGENCY.

THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY.

PEER NETWORK PEER-TO-PEER PROGRAM GUIDELINES

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

All program communication between mentors and mentees occurs via a secure e-mail system, and are intended to be private, one-on-one conversations. United Therapeutics Corporation and/or its agents will not monitor or view mentor/mentee communications except as required by law.

To help protect your privacy, we strongly advise program participants to refrain from sharing personally identifiable information (including name, address, phone number, and e-mail) with one another and to utilize the program website for all communication.

The information exchanged through the program does not represent medical advice. Seek professional medical advice before initiating any form of treatment. Never disregard medical advice, delay seeking it, or alter, cease, or modify your treatment without first consulting your physician or other healthcare provider. The opinions of the PEER Mentors are independent and do not necessarily reflect the opinions and policies of United Therapeutics Corporation.

You may opt out of the PEER Network program at any time, for any reason. All PEER Network e-mails sent to you after registering include an opt-out option. You can also e-mail the Network at info@peernetwork.net or call 1-866-505-7337 at any time to opt out.

ABOUT THE INFORMATION ON THIS WEBSITE

Much of the information on this website relates to products and services offered by United Therapeutics Corporation. The materials on this website are for your general educational information only. Information you read on this website cannot replace the relationship that you have with your healthcare professional. United Therapeutics Corporation does not practice medicine or provide medical services or advice and the information on this website should not be considered medical advice. You should always talk to your healthcare professional for diagnosis and treatment.

Health information changes quickly. Therefore, it is always best to confirm information with your healthcare professional.

This website contains information about products and therapies authorized in the United States, and is intended only for a United States audience. If you live outside the U.S., you may see information on this website about products or therapies that are not available or authorized in your country.

The materials on this website belong to or are licensed to us. The materials are protected by United States and foreign copyright laws. You may e-mail, download, or print copies of the materials on this website, but only for your personal, noncommercial use. When you e-mail, download, or print a copy of the materials on this website, you must also include all copyright and other notices that are in the materials, including the copyright notice on the bottom of the page.

The names, marks, and logos appearing on this site are, unless otherwise noted, trademarks owned by or licensed to United Therapeutics Corporation or an affiliated company. These items are protected by United States and foreign trademark laws. A ® following a name on our website indicates that the trademark has been registered in the United States. A following a name on our website indicates that it is an unregistered trademark. All trademarks are the property of their respective owners.

There may be special rules for the use of materials provided on certain parts of this website. These special rules will be posted near the materials.

If you use the materials or trademarks on this website in a way that is not clearly allowed by these Terms of Use, you are violating your agreement with us and may be violating copyright, trademark, and other laws. Any use of our marks contrary to these terms and conditions will result in the automatic revocation of your permission to use this website. Title to the materials remains with us or with the authors of the materials contained on this website. All rights not expressly granted are reserved.

You are hereby granted a non-exclusive, limited, and revocable license to link to this website. United Therapeutics Corporation reserves the right to revoke this license at any time. If United Therapeutics Corporation revokes this license, you agree to cease accessing and linking to this website for any purpose immediately.

You agree not to present the link to this website in such a way that it is associated with advertising or appears to be an endorsement of any organization, product, or service. You agree that any link you provide will not appear on a website that a reasonable person may consider obscene, defamatory, harassing, grossly offensive, or malicious. Under no circumstances may you "frame" this website or any of its content or copy portions of this website to a server. You agree not to display or use the United Therapeutics Corporation logo or trademark in any manner without our prior written permission.

This website may contain links to websites not operated by United Therapeutics Corporation. We provide these links for your convenience, but we do not review, control, or monitor the materials on any other websites. These websites may contain information about uses of United Therapeutics Corporation products or therapies that have not been approved in the United States. We do not control or endorse this type of information. We are not responsible for the performance of those websites or for your business dealings with them. Your use of other websites is subject to the terms of use of those websites, including the privacy policies of those websites. If you decide to visit any third-party sites using links from this website, you do so at your own risk.

YOUR FEEDBACK, COMMENTS, AND IDEAS

While we are pleased to receive feedback, comments, and ideas from visitors to this website, we want you to understand that any information that you submit through this website will be considered non-personal, non-confidential, and non-proprietary (other than personal information, as that term is defined in our Privacy Policy). If you transmit any ideas, information, concepts, know-how or techniques, or materials to us through this website, you hereby grant United Therapeutics Corporation an unrestricted, royalty-free, irrevocable license to use, reproduce, display, perform, modify, transmit, and distribute them in any medium, and agree that United Therapeutics Corporation is free to use them for any purpose.

As a user of this website, you are responsible for your own communications and the consequences of posting them. Therefore, do not do any of the following things: transmit to us material that is copyrighted, unless you are the exclusive copyright owner or have the permission of all the copyright owners to post it; send material that reveals trade secrets, unless you own them or have the permission of the owner; send material that infringes on any other intellectual property rights of others or on the privacy or publicity rights of others; send material that is obscene, defamatory, threatening, harassing, abusive, hateful, or embarrassing to another user or any other person or entity; send sexually-explicit images; send advertisements or solicitations of business; send chain letters or descriptions of or invitations to participate in pyramid schemes; or impersonate another person. If the company learns or suspects that you may have posted material in violation of these rules, it will remove that material pending further investigation.

If you believe that anything posted on the company's site infringes or may infringe the rights of others, including copyright, please notify us using the following e-mail address: legal@unither.com. We will investigate the claim and take appropriate action in response.

LIMITATION OF LIABILITY

Although we strive for accuracy in all information presented on this website, this website may contain inaccuracies or typographical errors. Additionally, while users of this website and participants in the PEER Network are bound by these terms and conditions and the program terms and conditions not to submit or present false or misleading material, the company cannot be responsible for the violation of these terms by users, or for the reliance by users upon false or misleading material submitted by other users. The company makes no representations about the accuracy, reliability, validity, completeness, or timeliness of the material on this website or about the results to be obtained from using the website or from relying on its material. You use the website and its material at your own risk. The site material may not always be the most current source of information, and the company disclaims any duty to update this website or the site material, and also disclaims liability for any failure to update this website or the site material.

NO WARRANTIES

THE COMPANY DOES NOT WARRANT THAT THE WEBSITE WILL OPERATE ERROR-FREE OR THAT THE WEBSITE AND ITS SERVER ARE FREE OF COMPUTER VIRUSES, WORMS, OR OTHER HARMFUL MATERIAL. IF YOUR USE OF THE WEBSITE OR THE SITE'S MATERIAL RESULTS IN ANY COSTS OR EXPENSES, INCLUDING, WITHOUT LIMITATION, THE NEED FOR SERVICING OR REPLACING EQUIPMENT OR DATA, THE COMPANY SHALL NOT BE RESPONSIBLE FOR THOSE COSTS OR EXPENSES. THIS WEBSITE AND ITS MATERIAL ARE PROVIDED ON AN "AS IS" BASIS WITHOUT ANY WARRANTIES OF ANY KIND. TO THE FULLEST EXTENT PERMITTED BY LAW, THE COMPANY DISCLAIMS ALL WARRANTIES, INCLUDING WITHOUT LIMITATION THE WARRANTY OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES' RIGHTS, AND THE WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. ALTHOUGH THE COMPANY STRIVES TO PROVIDE THOROUGH AND ACCURATE MATERIALS ON ITS SITE, WE MAKE NO WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS, OR TIMELINESS OF THE MATERIAL, SERVICES, SOFTWARE, TEXT, GRAPHICS, AND LINKS.

Disclaimer of Damages

IN NO EVENT SHALL THE COMPANY, ITS AFFILIATES, OR ANY THIRD PARTIES MENTIONED ON THE SITE BE LIABLE FOR ANY DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE OR EXEMPLARY DAMAGES, LOST PROFITS, OR DAMAGES RESULTING FROM LOST DATA OR BUSINESS INTERRUPTION) RESULTING FROM THE USE OR INABILITY TO USE MATERIAL ON THIS WEBSITE OR SITES LINKED TO THIS WEBSITE, WHETHER BASED ON WARRANTY, CONTRACT, TORT, OR ANY OTHER LEGAL THEORY, AND WHETHER OR NOT THE COMPANY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

Indemnity

By using this website, you agree to defend, indemnify, and hold harmless the company, its officers, directors, employees, and agents from and against any and all losses, claims, damages, costs, and expenses (including reasonable legal and accounting fees) that the company may become obligated to pay arising or resulting from your use of the site material or your breach of these Terms and Conditions. The company reserves the right to assume or participate, at your expense, in the investigation, settlement and defense of any such action or claim.

OTHER RULES ABOUT THIS WEBSITE

In addition to the rules in these Terms of Use and the Privacy Policy, you may be subject to additional terms that may apply when you access particular services or materials on certain areas in this website, such as when you submit registration information for the PEER Network. Please read our Privacy Policy to learn how we protect and use information that we gather through this website.

Your obligations under this section and the sections called "Your Feedback, Comments, and Ideas", "Limitation of Liability", "No Warranties", and “Indemnity” will survive termination of these Terms of Use.

If any provision of these Terms of Use is found to be invalid by any court having competent jurisdiction, the invalidity of such provision shall not affect the validity of the remaining provisions of these Terms of Use, which shall remain in full force and effect. No waiver of any of these Terms of Use shall be deemed a further or continuing waiver of such term or condition or any other term or condition.

If you violate these Terms of Use or the Privacy Policy in a way that causes harm to others, you agree to hold United Therapeutics Corporation harmless against any liability for that harm.

By using this website, you agree that the only available jurisdiction and venue for any dispute with United Therapeutics Corporation, or in any way relating to your use of this website, is in the state and federal courts in the State of Maryland, U.S.A. You further agree and consent to the exercise of personal jurisdiction in these courts in connection with any dispute involving United Therapeutics Corporation or its affiliates, employees, officers, directors, agents, or suppliers.

These Terms of Use are governed by the internal substantive laws of the State of Maryland, without respect to its conflict of laws, principles, and the federal laws of the United States.

All questions about Privacy are addressed by the Privacy Policy.

QUESTIONS, COMMENTS, AND NOTICES

United Therapeutics Corporation may deliver notice to you by electronic mail, a general notice on this website, or by written communication delivered by First Class U.S. Mail to your address on record with United Therapeutics Corporation. You may deliver notice to United Therapeutics Corporation by using the Contact United Therapeutics Corporation feature, or at:

United Therapeutics Corporation
General Counsel
1735 Connecticut Ave NW, 2nd Floor
Washington, DC 20009

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Orenitram® (treprostinil) Extended-Release Tablets

INDICATION

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram may improve your ability to exercise. It is not known if Orenitram is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION for Orenitram

Do not take Orenitram if you have severe liver problems.

Before you take Orenitram, tell your healthcare provider if you:

  • Have liver problems, diverticulosis, or any other medical conditions
  • Are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. You and your healthcare provider should decide if you will take Orenitram or breastfeed. You should not do both

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start or stop any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains the same ingredient, treprostinil. Know the medicines you take. Keep a list of them and the dose you take to show to your healthcare provider and pharmacist when you get a new medicine.

Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider. Stopping Orenitram suddenly may cause worsening of your PAH symptoms. If you miss two or more doses of Orenitram, call your healthcare provider. If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.

If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. Take Orenitram with food.

Orenitram can cause serious side effects, including an increased risk of bleeding. This risk could be increased if you are taking blood thinners such as warfarin.

The most common side effects of Orenitram include headache, diarrhea, nausea and flushing. These are not all of the possible side effects of Orenitram. Tell your doctor about any side effects that bother you, get worse over time, or do not go away.

OREISIdtcJAN16

Please see the Full Prescribing information and Patient Information for Orenitram.

For more information about Orenitram, visit www.orenitram.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Tyvaso® (treprostinil) Inhalation Solution

INDICATION

Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.

The effects of Tyvaso are unknown in patients under 18 years of age.

IMPORTANT SAFETY INFORMATION for Tyvaso

  • Tyvaso is breathed in (inhalable) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.

Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a lung disease (such as asthma or chronic obstructive pulmonary disease (COPD)).
  • Have a lung infection.
  • Have liver or kidney problems, as your ability to tolerate Tyvaso may be affected.
  • Have low blood pressure, as Tyvaso may cause symptomatic hypotension (low blood pressure).
  • Are pregnant or plan to become pregnant. It is not known if Tyvaso will harm your unborn baby. Women who can become pregnant should use effective birth control while taking Tyvaso.
  • Are breast-feeding or plan to breast-feed. It is not known if Tyvaso passes into your breast milk.

It is important to tell your healthcare provider about all the medicines you may be taking, including prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare provider if you take any of these medicines:

  • Medicines that decrease blood clotting such as warfarin or heparin, as Tyvaso reduces the ability of your blood to clot (coagulate), and increases your risk for bleeding if you are taking blood thinners (anticoagulants).
  • Diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure), as Tyvaso may increase your risk for hypotension (low blood pressure).
  • Gemfibrozil such as Lopid (for high cholesterol) or rifampin such as Rimactane, Rifadin, Rifamate or Rifater (for infection), as your Tyvaso dosage may need adjustment.

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do not go away. Your healthcare provider may be able to help you manage the side effects.

TYVISIdtcJUN16

Please see the Full Prescribing Information, Patient Package Insert, and Tyvaso Inhalation System Instructions for Use Manual.

For more information about Tyvaso, visit www.tyvaso.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Remodulin® (treprostinil) Injection

INDICATION

Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.

In patients with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.

IMPORTANT SAFETY INFORMATION for Remodulin

  • Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest. This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
  • You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen.
  • Other medical conditions and medicines may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug's effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking.
  • If you have liver or kidney problems, your ability to tolerate Remodulin may be affected.
  • If you are taking gemfibrozil (for high cholesterol), rifampin (for infection), or other drugs that affect liver enzymes, your doctor may need to adjust your Remodulin dosage.
  • Remodulin acts by lowering your blood pressure. In some cases your blood pressure may become too low and cause other side effects. If you also take other drugs that lower your blood pressure, the risk is increased. You should discuss all of your symptoms with your doctor, including those associated with low blood pressure.
  • Because Remodulin can reduce the blood's ability to clot, it may increase your risk of bleeding, especially if you are taking anticoagulants (blood thinners).
  • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your doctor about whether you should take Remodulin.
  • Side Effects: In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness and swelling). These symptoms were often severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain. Other common side effects seen with either SC or IV Remodulin were headache, diarrhea, jaw pain, nausea, vasodilatation (widening of the blood vessels), and edema (swelling).

Please see the Full Prescribing Information for Remodulin.

For more information about Remodulin, visit www.remodulin.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Orenitram, Tyvaso, and Remodulin are registered trademarks of United Therapeutics Corporation.

All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.